Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
middlebrookpharma.com

See what CB Insights has to offer

Founded Year

1999

Stage

Dead | Dead

Total Raised

$105.66M

About Middlebrook Pharmaceuticals

MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products that fulfill unmet medical needs. It was formerly known as Advancis Pharmaceuticals. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG - the first and only FDA-approved once-daily amoxicillin. nnThe companyhas developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MOXATAG is our first product utilizing our proprietary PULSYS technology. While MiddleBrook is currently focused on the anti-infective arena, we see opportunities for PULSYS products in the anti-fungal, antiviral, and oncology markets as well.

Middlebrook Pharmaceuticals Headquarter Location

20425 Seneca Meadows Parkway Suite 100

Germantown, Maryland, 20876,

United States

301-944-6600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Middlebrook Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Middlebrook Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.